Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m(2) of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m(2) of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Roboz, Gail J., Mandrekar, Sumithra J., Desai, Pinkal, Laumann, Kristina, Walker, Alison R., Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Attar, Eyal C., Stock, Wendy, Bloomfield, Clara D., Kohlschmidt, Jessica, Mrózek, Krzysztof, Hassane, Duane C., Garraway, Levi, Jané-Valbuena, Judit, Baltay, Michele, Tracy, Adam, Marcucci, Guido, Stone, Richard M., Larson, Richard A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306886/
https://ncbi.nlm.nih.gov/pubmed/30567725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018023689
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares